Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Intranasal administration of SARS-CoV-2 neutralizing human antibody prevents infection in mice

Hongbing Zhang, Zhiyuan Yang, Jingyi Xiang, Ziyou Cui, Jianying Liu, Cheng Liu
doi: https://doi.org/10.1101/2020.12.08.416677
Hongbing Zhang
1Eureka Therapeutics, Inc., Emeryville, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhiyuan Yang
1Eureka Therapeutics, Inc., Emeryville, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingyi Xiang
1Eureka Therapeutics, Inc., Emeryville, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ziyou Cui
1Eureka Therapeutics, Inc., Emeryville, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianying Liu
1Eureka Therapeutics, Inc., Emeryville, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheng Liu
1Eureka Therapeutics, Inc., Emeryville, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cheng.liu@eurekainc.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

Prevention of SARS-CoV-2 infection at the point of nasal entry is a novel strategy that has the potential to help contain the ongoing pandemic. Using our proprietary technologies, we have engineered a human antibody that recognizes SARS-CoV-2 S1 spike protein with an enhanced affinity for mucin to improve the antibody’s retention in respiratory mucosa. The modified antibody, when administered into mouse nostrils, was shown to block infection in mice that were exposed to high titer SARS-CoV-2 pseudovirus 10 hours after the initial antibody treatment. Our data show that the protection against SARS-CoV-2 infection is effective in both nasal and lung areas 7 days after viral exposure. The modified antibody is stable in a nasal spray formulation and maintains its SARS-CoV-2 neutralizing activity. Nasal spray of the modified antibody can be developed as an affordable and effective prophylactic product to protect people from infection by exposure to SARS-CoV-2 virus in the air.

One-sentence summary A Fc-modified human antibody prevents SARS-CoV-2 viral infection via nasal administration

Competing Interest Statement

The authors are all employees from biotechnology company Eureka Therapeutics, inc.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 09, 2020.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Intranasal administration of SARS-CoV-2 neutralizing human antibody prevents infection in mice
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Intranasal administration of SARS-CoV-2 neutralizing human antibody prevents infection in mice
Hongbing Zhang, Zhiyuan Yang, Jingyi Xiang, Ziyou Cui, Jianying Liu, Cheng Liu
bioRxiv 2020.12.08.416677; doi: https://doi.org/10.1101/2020.12.08.416677
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Intranasal administration of SARS-CoV-2 neutralizing human antibody prevents infection in mice
Hongbing Zhang, Zhiyuan Yang, Jingyi Xiang, Ziyou Cui, Jianying Liu, Cheng Liu
bioRxiv 2020.12.08.416677; doi: https://doi.org/10.1101/2020.12.08.416677

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Bioengineering
Subject Areas
All Articles
  • Animal Behavior and Cognition (2416)
  • Biochemistry (4774)
  • Bioengineering (3319)
  • Bioinformatics (14626)
  • Biophysics (6617)
  • Cancer Biology (5156)
  • Cell Biology (7402)
  • Clinical Trials (138)
  • Developmental Biology (4340)
  • Ecology (6858)
  • Epidemiology (2057)
  • Evolutionary Biology (9876)
  • Genetics (7328)
  • Genomics (9496)
  • Immunology (4534)
  • Microbiology (12631)
  • Molecular Biology (4919)
  • Neuroscience (28206)
  • Paleontology (198)
  • Pathology (802)
  • Pharmacology and Toxicology (1380)
  • Physiology (2012)
  • Plant Biology (4473)
  • Scientific Communication and Education (974)
  • Synthetic Biology (1295)
  • Systems Biology (3903)
  • Zoology (722)